Premed · Premed · Biochemistry
Lecture 28: Course Review and Clinical Correlations
Biochemistry
Learning Objectives
By the end of this lecture, students will be able to:
- Integrate the major metabolic pathways into a unified whole-body framework
- Identify the key regulatory enzymes and their allosteric effectors across all major pathways
- Apply biochemical principles to clinical scenarios involving metabolic disease
- Recognize the biochemical basis of common inherited metabolic disorders
- Connect vitamin and cofactor functions to their associated deficiency diseases
- Synthesize knowledge of molecular biology (replication, transcription, translation) with clinical applications
Lecture Content
I. Integrated Metabolic Map — The Big Picture
Central Metabolic Pathways and Their Connections:
Glucose-6-phosphate is a critical branch point: Glycolysis (energy production) Pentose phosphate pathway (NADPH and ribose-5-phosphate) Glycogenesis (storage) Released as free glucose (liver only, via glucose-6-phosphatase).
Pyruvate is a central metabolic hub: From glycolysis (glucose -> pyruvate) To acetyl-CoA (pyruvate dehydrogenase; irreversible) To oxaloacetate (pyruvate carboxylase; gluconeogenesis, anaplerosis) To lactate (lactate dehydrogenase; anaerobic conditions) To alanine (ALT; amino acid metabolism).
Acetyl-CoA connects carbohydrate, fat, and amino acid metabolism: From pyruvate (carbohydrates), beta-oxidation (fatty acids), amino acid catabolism. To TCA cycle (energy production) To fatty acid synthesis (lipogenesis; fed state) To ketone bodies (ketogenesis; fasting) To cholesterol synthesis. Cannot be converted to glucose (acetyl-CoA -> OAA is not possible because TCA cycle carbons are lost as CO2).
Oxaloacetate (OAA) links the TCA cycle to gluconeogenesis: OAA -> PEP (PEPCK) -> gluconeogenesis. OAA + acetyl-CoA -> citrate (TCA cycle entry) OAA <-> aspartate (transamination; connects to urea cycle).
The Three Irreversible Steps of Glycolysis (and Their Gluconeogenesis Bypasses):
| Glycolytic Enzyme | Gluconeogenesis Bypass |
|---|---|
| Hexokinase/glucokinase | Glucose-6-phosphatase (liver, kidney) |
| PFK-1 | Fructose-1,6-bisphosphatase |
| Pyruvate kinase | Pyruvate carboxylase + PEPCK |
II. Master Table of Key Regulatory Enzymes
| Pathway | Rate-Limiting / Key Enzyme | Activators | Inhibitors |
|---|---|---|---|
| Glycolysis | PFK-1 | AMP, F2,6-BP, insulin | ATP, citrate, glucagon (via decreased F2,6-BP) |
| Gluconeogenesis | F1,6-BPase | ATP, citrate, glucagon | AMP, F2,6-BP, insulin |
| Glycogenesis | Glycogen synthase | G6P, insulin (dephosphorylation) | Glucagon, epinephrine (phosphorylation by PKA) |
| Glycogenolysis | Glycogen phosphorylase | AMP (muscle), Ca2+, glucagon, epinephrine | ATP, G6P, insulin |
| TCA cycle | Isocitrate dehydrogenase | ADP, Ca2+ | ATP, NADH |
| PDH complex | Pyruvate dehydrogenase | CoA, NAD+, ADP, Ca2+, insulin | Acetyl-CoA, NADH, ATP (PDH kinase) |
| PPP | G6PD | NADP+ | NADPH |
| Fatty acid synthesis | ACC | Citrate, insulin | Palmitoyl-CoA, AMPK, glucagon |
| Beta-oxidation | CPT-I | Glucagon (decreases malonyl-CoA) | Malonyl-CoA, insulin |
| Ketogenesis | HMG-CoA synthase | Glucagon, increased acetyl-CoA | Insulin |
| Cholesterol synthesis | HMG-CoA reductase | Insulin, SREBP | Cholesterol, statins, glucagon |
| Urea cycle | CPS-I | N-acetylglutamate (activated by arginine) | — |
| Purine synthesis | Glutamine-PRPP amidotransferase | PRPP | IMP, AMP, GMP |
| Pyrimidine synthesis | CPS-II | ATP, PRPP | UTP |
III. Vitamins and Cofactors — Comprehensive Review
Water-Soluble Vitamins:
| Vitamin | Active Form | Key Functions | Deficiency |
|---|---|---|---|
| B1 (Thiamine) | TPP | PDH, alpha-KG DH, branched-chain alpha-keto acid DH, transketolase | Beriberi (wet/dry), Wernicke-Korsakoff syndrome |
| B2 (Riboflavin) | FAD, FMN | Electron carrier in redox reactions (succinate DH, acyl-CoA DH, DHODH) | Cheilosis, corneal vascularization |
| B3 (Niacin) | NAD+, NADP+ | Electron carrier in redox reactions; substrate for ADP-ribosylation | Pellagra (diarrhea, dermatitis, dementia) |
| B5 (Pantothenate) | CoA, ACP | Acyl group carrier (FA synthesis, TCA cycle, beta-oxidation) | Rare; dermatitis, enteritis |
| B6 (Pyridoxine) | PLP | Transamination, decarboxylation, glycogen phosphorylase, heme synthesis (ALA synthase), cystathionine synthase | Peripheral neuropathy, sideroblastic anemia, seizures |
| B7 (Biotin) | Biotin | CO2 carrier in carboxylation reactions (pyruvate carboxylase, ACC, propionyl-CoA carboxylase) | Rare; dermatitis, alopecia (raw egg whites; avidin binds biotin) |
| B9 (Folate) | THF | One-carbon transfers (dTMP synthesis, purine synthesis, methionine regeneration) | Megaloblastic anemia, neural tube defects |
| B12 (Cobalamin) | Methylcobalamin, adenosylcobalamin | Methionine synthase (methylcobalamin); methylmalonyl-CoA mutase (adenosylcobalamin) | Megaloblastic anemia, subacute combined degeneration, methylmalonic acidemia |
| C (Ascorbic acid) | Ascorbate | Hydroxylation of proline and lysine in collagen (prolyl/lysyl hydroxylase); antioxidant; dopamine beta-hydroxylase; iron absorption | Scurvy (poor wound healing, gingival bleeding, perifollicular hemorrhages) |
Fat-Soluble Vitamins (A, D, E, K):
| Vitamin | Key Functions | Deficiency |
|---|---|---|
| A (Retinol) | Vision (retinal in rhodopsin), cell differentiation, growth, immune function | Night blindness, xerophthalmia, Bitot spots, keratomalacia |
| D (Cholecalciferol) | Calcium and phosphate homeostasis (increases intestinal Ca2+ absorption, bone mineralization) | Rickets (children), osteomalacia (adults) |
| E (Tocopherol) | Antioxidant (protects membrane polyunsaturated fatty acids from lipid peroxidation) | Hemolytic anemia (fragile RBCs), neurological dysfunction |
| K (Phylloquinone/menaquinone) | Gamma-carboxylation of glutamate residues in clotting factors (II, VII, IX, X, protein C and S) | Bleeding diathesis, increased PT/INR; hemorrhagic disease of the newborn |
<image>A comprehensive metabolic integration map showing the interconnection of all major pathways. The diagram is organized around a central TCA cycle, with radiating connections to: glycolysis and gluconeogenesis (top left, with glucose-6-phosphate as a branch point to the pentose phosphate pathway and glycogen metabolism), fatty acid synthesis and beta-oxidation (top right, connected via acetyl-CoA and malonyl-CoA), amino acid catabolism feeding into TCA intermediates and the urea cycle (bottom left), ketogenesis branching from acetyl-CoA (bottom right), and oxidative phosphorylation coupled to the electron transport chain (bottom center). Key regulatory enzymes are highlighted in red boxes with their activators (green arrows) and inhibitors (red arrows). The flow of carbon (black arrows), nitrogen (blue arrows), and electrons (orange arrows through NAD+/NADH and FAD/FADH2 to the ETC) are color-coded. Hormonal control is overlaid: insulin promoting storage and synthesis (anabolic, green shading), glucagon promoting mobilization and oxidation (catabolic, red shading).</image>
IV. High-Yield Clinical Correlations by System
A. Carbohydrate Metabolism Disorders
| Disorder | Enzyme Deficiency | Key Features |
|---|---|---|
| Von Gierke disease (GSD I) | Glucose-6-phosphatase | Severe fasting hypoglycemia, hepatomegaly, lactic acidosis, hyperlipidemia, hyperuricemia |
| Pompe disease (GSD II) | Acid maltase (alpha-1,4-glucosidase, lysosomal) | Cardiomegaly, hypotonia, early death (infantile form); lysosomal glycogen accumulation |
| McArdle disease (GSD V) | Muscle glycogen phosphorylase | Exercise intolerance, myoglobinuria, no rise in blood lactate with exercise |
| Galactosemia (classic) | Galactose-1-phosphate uridylyltransferase | Cataracts, hepatomegaly, intellectual disability; galactitol accumulation |
| Fructose intolerance (hereditary) | Aldolase B | Hypoglycemia after fructose ingestion (F1P traps phosphate, inhibits glycogenolysis and gluconeogenesis) |
| Pyruvate dehydrogenase deficiency | PDH complex (E1 subunit) | Lactic acidosis, neurological deficits; X-linked; dietary ketogenic diet may help |
| G6PD deficiency | Glucose-6-phosphate dehydrogenase | Hemolytic anemia triggered by oxidative stress (fava beans, sulfonamides, primaquine); Heinz bodies |
B. Lipid Metabolism Disorders
| Disorder | Defect | Key Features |
|---|---|---|
| Familial hypercholesterolemia | LDL receptor mutations | Severely elevated LDL cholesterol, xanthomas, premature atherosclerosis, MI |
| MCAD deficiency | Medium-chain acyl-CoA dehydrogenase | Hypoketotic hypoglycemia, dicarboxylic aciduria; triggered by fasting |
| Carnitine deficiency | Carnitine transporter or CPT deficiency | Impaired FA oxidation, muscle weakness, hypoketotic hypoglycemia |
| Abetalipoproteinemia | Microsomal triglyceride transfer protein (MTP) | Cannot form chylomicrons or VLDL; fat malabsorption, acanthocytosis, fat-soluble vitamin deficiency |
| Sphingolipidoses (Tay-Sachs, Gaucher, Niemann-Pick, Fabry, Krabbe) | Lysosomal enzyme deficiencies | Accumulation of specific sphingolipids; neurodegeneration (many); hepatosplenomegaly |
C. Amino Acid and Nitrogen Metabolism Disorders
| Disorder | Defect | Key Features |
|---|---|---|
| PKU | Phenylalanine hydroxylase (or BH4) | Intellectual disability, musty odor, fair skin; treated with low-Phe diet |
| Maple syrup urine disease | Branched-chain alpha-keto acid DH complex | Sweet-smelling urine, neurological damage; elevated Leu, Ile, Val |
| Homocystinuria | Cystathionine beta-synthase (most common) | Lens subluxation (downward), marfanoid, thromboembolism, intellectual disability |
| Alkaptonuria | Homogentisic acid oxidase (tyrosine degradation) | Dark urine, ochronosis (dark connective tissue pigmentation), arthritis |
| OTC deficiency | Ornithine transcarbamylase | Hyperammonemia, elevated orotic acid in urine; X-linked |
| CPS-I deficiency | Carbamoyl phosphate synthetase I | Hyperammonemia; no orotic acid elevation (distinguishes from OTC deficiency) |
D. Nucleotide Metabolism Disorders
| Disorder | Defect | Key Features |
|---|---|---|
| Gout | Uric acid overproduction or underexcretion | Acute arthritis (podagra), tophi, renal stones; treated with allopurinol, colchicine |
| Lesch-Nyhan syndrome | HGPRT deficiency | Hyperuricemia, self-mutilation, intellectual disability, choreoathetosis; X-linked |
| ADA deficiency | Adenosine deaminase | SCID (severe combined immunodeficiency); dATP accumulates, inhibits RNR |
| Orotic aciduria | UMP synthase | Megaloblastic anemia (not responsive to folate/B12), orotic acid in urine; treated with uridine |
V. Molecular Biology — Clinical Connections
| Topic | Clinical Application |
|---|---|
| DNA replication | Nucleoside analogs (acyclovir, AZT) as antivirals; topoisomerase inhibitors as anticancer agents |
| DNA repair | XP (NER defect), Lynch syndrome (MMR defect), BRCA1/2 (HR defect; breast/ovarian cancer) |
| Transcription | Rifampin (TB treatment, inhibits bacterial RNA Pol); alpha-amanitin poisoning (mushroom, inhibits RNA Pol II) |
| RNA processing | Beta-thalassemia (splicing mutations); SMA (treated by splicing modulation with nusinersen); anti-Smith antibodies in SLE |
| Translation | Antibiotics targeting bacterial ribosomes (tetracycline, aminoglycosides, macrolides, chloramphenicol); diphtheria toxin (ADP-ribosylates eEF2) |
| Protein targeting | I-cell disease (M6P tagging defect); signal peptide mutations causing protein mislocalization |
| Post-translational modification | Scurvy (defective collagen hydroxylation); warfarin (inhibits vitamin K-dependent gamma-carboxylation of clotting factors) |
| Protein folding | Cystic fibrosis (delta-F508 CFTR misfolding); prion diseases (PrPSc misfolding); alpha-1 antitrypsin deficiency (polymerization in ER) |
VI. Metabolic States — Quick Reference
| State | Insulin:Glucagon | Liver | Muscle | Adipose | Brain |
|---|---|---|---|---|---|
| Fed | High | Glycolysis, lipogenesis, glycogenesis | Glucose uptake, glycogenesis, protein synthesis | Lipogenesis, glucose uptake | Glucose |
| Early fasting | Low | Glycogenolysis, beginning gluconeogenesis | FA oxidation, glycogenolysis | Lipolysis begins | Glucose |
| Prolonged fasting | Very low | Gluconeogenesis, ketogenesis, beta-oxidation | FA and ketone body oxidation, proteolysis | Lipolysis | Glucose + ketone bodies |
| Starvation | Very low | Gluconeogenesis (decreased), ketogenesis (high) | Ketone body oxidation, protein sparing | Lipolysis (fat stores depleted) | Ketone bodies (60-70%) + glucose |
| Exercise | Low (+ epinephrine) | Glycogenolysis, gluconeogenesis | Glycogenolysis, glycolysis -> FA oxidation | Lipolysis | Glucose |
<image>A clinical decision flowchart for diagnosing inherited metabolic disorders based on laboratory findings. The flowchart starts with initial lab findings and branches: (1) Hyperammonemia -> check urine orotic acid: elevated = OTC deficiency, normal = CPS-I deficiency. (2) Metabolic acidosis with elevated lactate -> check pyruvate: elevated pyruvate with normal L:P ratio = PDH deficiency, elevated L:P ratio = ETC/oxidative phosphorylation defect. (3) Hypoglycemia -> check ketones: hypoketotic = fatty acid oxidation defect (MCAD) or hyperinsulinism; ketotic = GSD or gluconeogenesis defect. (4) Elevated uric acid -> check HGPRT activity: absent with neurological symptoms = Lesch-Nyhan; present = primary gout. (5) Megaloblastic anemia -> check response to folate/B12: responsive = folate or B12 deficiency; non-responsive with orotic aciduria = UMP synthase deficiency. Each endpoint lists the disorder name, the deficient enzyme, and first-line treatment.</image>
VII. High-Yield Equations and Energy Accounting
ATP Yield from Complete Oxidation of Glucose (Aerobic):
Glycolysis: Glucose -> 2 Pyruvate (net 2 ATP + 2 NADH) Pyruvate dehydrogenase: 2 Pyruvate -> 2 Acetyl-CoA (2 NADH) TCA cycle (x2): 6 NADH + 2 FADH2 + 2 GTP. Oxidative phosphorylation: NADH -> ~2.5 ATP; FADH2 -> ~1.5 ATP. Total: ~30-32 ATP per glucose (depending on the shuttle used for cytoplasmic NADH: malate-aspartate shuttle = 2.5 ATP/NADH; glycerol-3-phosphate shuttle = 1.5 ATP/NADH).
ATP Yield from Palmitate (C16:0) Oxidation:
Activation: -2 ATP equivalents (ATP -> AMP + PPi) 7 cycles of beta-oxidation: 7 FADH2 (7 x 1.5 = 10.5 ATP) + 7 NADH (7 x 2.5 = 17.5 ATP) 8 Acetyl-CoA -> 8 turns of TCA: 8 x 10 = 80 ATP (each acetyl-CoA yields 3 NADH + 1 FADH2 + 1 GTP = 10 ATP) Total: 106 ATP per palmitate (108 - 2 for activation).
Urea Cycle Cost:
3 ATP consumed (but 4 high-energy bonds used: 2 ATP -> 2 ADP + 1 ATP -> AMP + PPi) Partially offset by fumarate re-entering TCA cycle (fumarate -> malate -> OAA generates 1 NADH = 2.5 ATP).
